Drug Approval | May 30, 2024
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Launch of 20 new medicines expected by 2030
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Subscribe To Our Newsletter & Stay Updated
